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Myelination, which occurs predominantly postnatally and continues throughout life, is
important for proper neurologic function of the mammalian central nervous system
(CNS). We have previously demonstrated that the combination therapy of fingolimod
(FTY720) and transplanted neural stem cells (NSCs) had a significantly enhanced
therapeutic effect on the chronic stage of experimental autoimmune encephalomyelitis,
an animal model of CNS autoimmunity, compared to using either one of them alone.
However, reduced disease severity may be secondary to the immunomodulatory effects
of FTY720 and NSCs, while whether this therapy directly affects myelinogenesis remains
unknown. To investigate this important question, we used three myelination models
under minimal or non-inflammatory microenvironments. Our results showed that FTY720
drives NSCs to differentiate into oligodendrocytes and promotes myelination in an ex
vivo brain slice culture model, and in the developing CNS of healthy postnatal mice
in vivo. Elevated levels of neurotrophic factors, e.g., brain-derived neurotrophic factor
and glial cell line-derived neurotrophic factor, were observed in the CNS of the treated
infant mice. Further, FTY720 and NSCs efficiently prolonged the survival and improved
sensorimotor function of shiverer mice. Together, these data demonstrate a direct
effect of FTY720, beyond its known immunomodulatory capacity, in NSC differentiation
and myelin development as a novel mechanism underlying its therapeutic effect in
demyelinating diseases.
Keywords: fingolimod, neural stem cells, myelination, oligodendrocytes, combination therapy
INTRODUCTION
Inflammatory demyelination and axonal damage in the central nervous system (CNS) are
pathological hallmarks of the chronic stage of multiple sclerosis (MS), an autoimmune
demyelinating disorder that leads to severe neurological dysfunction (Plemel et al., 2017; Scolding
et al., 2017). Although considerable progress has been made in MS therapies to reduce disease
severity and progression, these therapies are only partially effective in the acute, but not the
chronic state of disease (Bramow et al., 2010; Bible, 2013). This may be because they are
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mainly immunomodulatory but lack the neuroregenerative
capacity to repair already damaged CNS tissue (Plemel
et al., 2017). One major goal in therapeutic repair is the
remyelination of demyelinated axons. Because remyelination
is a natural consequence of oligodendrocyte differentiation,
it involves promoting oligodendrocyte precursor cells (OPCs)
to differentiate into mature oligodendrocytes in demyelinated
lesions, thereby ensheathing axons with new myelin. Thus,
a therapeutic strategy that has both immunomodulatory and
(re)myelination effects is required to overcome the deficiency of
current MS treatments (Grossman et al., 2017).
Fingolimod (FTY720, Gilenya), a lipophilic sphingosine 1-
phosphate (S1P) analog, is the first oral therapy for MS
(Brinkmann et al., 2010). The primary effect of FTY720 is
blocking lymphocyte egress from lymphoid tissues, thereby
reducing CNS infiltration (Aktas et al., 2010). Apart from
its well-known immunomodulatory actions, there is evidence
that FTY720 and related compounds could exert direct effects
on the CNS, because of its lipophilic nature, as well as
the expression of S1P receptors on neuroglial cells (Hunter
et al., 2016). There is thus the possibility that FTY720 might
exert additional beneficial effects on MS disease progression
independent of its effect on lymphocyte sequestration in lymph
nodes (Miron et al., 2008b). Our previous study (Zhang et al.,
2017) demonstrated that FTY720, at nanomolar concentrations,
effectively protected neural stem cell (NSC) survival and
enhanced their development into mature oligodendrocytes in
vitro. In vivo studies in an animal model of MS, experimental
autoimmune encephalomyelitis (EAE), have shown significantly
enhanced effects of combination therapy with FTY720 and
NSCs, compared to either one alone, on clinical amelioration,
axon preservation, neural cell survival, and transplanted NSC
differentiation into mature oligodendrocytes, all of which are
frequently linked to improved remyelination and CNS repair
processes.
Despite extensive studies, however, some important issues
remain to be clarified. On the one hand, the neurologic recovery
of chronic EAE mice treated with FTY720 and NSCs might be
secondary to their immunomodulatory effects. On the other
hand, there are reports showing that FTY720 did not induce
remyelination in cuprizone- and lysophosphatidylcholine-
induced demyelination models. Therefore, whether the
combination therapy with FTY720 and NSCs could induce
myelination directly in a non-chemical, minimal or non-
inflammatory CNS microenvironment has not yet been studied.
The potential of FTY720 to enhance an NSC-based therapy for
MS, as well as other demyelinating disorders, remains to be
determined.
To address this issue, here we sought to investigate the role
of the FTY720/NSC combination during the myelination process
Abbreviations: BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-
derived neurotrophic factor; CNS, central nervous system; EAE, experimental
autoimmune encephalomyelitis; FTY720, fingolimod; GFAP, glial fibrillary acid
protein; MBP, myelin basic protein; MS, multiple sclerosis; NeuN, Neuronal
Nuclei; NFH, neurofilament; NSCs, neural stem cells; OLGs, oligodendrocytes;
OPCs, oligodendrocyte precursor cells; S1P, sphingosine 1-phosphate.
in three myelination models with minimal or non-immune
cell involvement, including organotypic slice culture, postnatal
oligodendrocyte maturation, as well as the shiverermouse model.
The combination therapy with FTY720 and NSCs was effective in
promoting precocious myelination in organotypic slice cultures,
and in vivo in early postnatal mouse pups. Treatment with
both FTY720 and NSCs, but not with FTY720 or NSCs
alone, significantly increased differentiation of transplanted
NSCs into oligodendrocytes in hypomyelinated shiverer brain.
The mechanism underlying the beneficial effect of FTY720 on
NSC directional differentiation and myelination has also been
addressed.
MATERIALS AND METHODS
Animals
All experimental procedures and protocols were approved by
the Thomas Jefferson University Institutional Animal Care and
Committee and were performed in accordance with the approved
institutional guidelines and regulations. C57BL/6, C3H, or
shiverer mice (C3H background) were purchased from Jackson
Laboratory (Bar Harbor, ME). Mice, 1–3 days after birth, were
used in all in vivo experiments.
NSC Generation
NSCs were generated from the SVZ area of C57BL/6 or C3H
mice (Jackson Laboratory, Bar Harbor, ME), 6–8 weeks of age,
and transduced with GFP as described previously (Li et al., 2016).
GFP is used for tracing transplanted NSCs in brain slice cultures.
NSCs without GFP expression at passages 5–15 were used in in
vivomyelination experiments.
Antibodies
Primary antibodies used for these studies were specific for:
myelin basic protein (MBP, Abcam), neuron (NeuN, Abcam),
neurofilament (NFH, Abcam), glial fibrillary acid protein
(GFAP, Abcam), adenomatous polyposis coli/CC1 (Millipore).
Appropriate fluorescent secondary antibodies were used (Alexa
Fluor, Invitrogen).
Organotypic Slice Culture Myelination
Analysis
Organotypic slice cultures were prepared from the forebrain
of C57/Bl6 mouse pups as previously described (Miron et al.,
2010). Following 3-day ex-vivo culture to allow debris clearance
and dissection recovery, dissociated single NSCs (2 µl, ∼5 ×
104 cells/slice) were transduced with lentivirus expressing GFP
and were pipetted directly onto brain slices, which had been
pre-treated with cytosine arabinoside to prevent endogenous
myelination (Nishimura et al., 1985). Meanwhile, FTY720 (1 nM)
was diluted in culture media and replaced daily. For myelin
maintenance studies, slices transduced with or without NSCs
were treated for the subsequent 14 days with FTY720. Slices
that were cultured with both NSCs and FTY720 served as
a co-treatment group, those that received either NSCs or
FTY720 alone served as single-treatment controls, and those
that were incubated with the same volume of culture medium
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served as a sham-treated control. Slices were cultured for 2
weeks and fixed in 4% paraformaldehyde (PFA, wt/vol) for 1 h
and blocked in 5% normal horse serum (GIBCO) and 0.3%
Triton-X-100 (Fisher Scientific) for 3 h at room temperature.
Primary antibodies diluted in block solution were applied
and washed out with PBS 3 times after 48-h incubation at
4◦C. Slices were then incubated with species-specific secondary
antibodies for 1 h at room temperature, followed by washing
with PBS 3 times. Immunofluorescence controls were routinely
prepared by omitting primary antibodies. Nuclei were stained
with DAPI. Slides were covered with mounting medium
(Vector Laboratories, Burlingame, CA, USA) and kept at room
temperature for further analysis.
Myelination During Postnatal Development
C57Bl/6 mice, 3 days after birth, were used in myelin
development experiments as previously described (From et al.,
2014). NSCs were prepared for transplantation as described for in
vitro culture. Male littermates of similar weights were randomly
enrolled in the following treatment groups: (1) NSC single-
treated group: dissociated single NSCs (2.0 × 105 cells/mouse)
were injected i.c.v. at day 3 postnatal under anesthesia on ice as
described (Zhang et al., 2017), and PBS injected i.p. daily. (2)
FTY720 single-treated group: FTY720 at a dose of 0.3mg/kg daily
was injected i.p. daily, and PBS injected i.c.v. at day 3 postnatal.
(3) Combination of FTY720 and NSC treatment group: NSCs
were injected i.c.v. at day 3 postnatal with FTY720 i.p. (0.3 mg/kg
daily) from the day of cell injection. (4) PBS-injected i.c.v. and i.p.
in the same way as described above served as control. Transverse
sections of spinal cord (L4-L5 segments) were harvested at
day 14 postnatal and processed for immunohistochemistry or
RNA extraction. The myelinated axons (NFH+MBP+) were
quantified within 5 random standard 500 µm2 fields in the
white matter of the ventral lumbar spinal cord for each
mouse. Immunohistochemistry was performed using different
antibodies following procedures described previously (Zhang
et al., 2017). At days 20–21 postnatal, behavioral assessments
(open-field test and rotating rod test) of littermate mice from
four different groups were performed based on published
protocols (From et al., 2014). Data were collected from three
separate mouse litters because variability between litters has been
reported.
FIGURE 1 | Co-treatment with FTY720 and NSCs promoted myelination in the brain slice culture model. (A) Schematic diagram illustrating experimental design
followed throughout this study. Slices obtained from newborn (P0-3) C57/Bl6 mouse pups were grown for 3 days, and NSCs (2 µl, ∼5 × 104 cells /slice) and/or
FTY720 (1 nM) were added for the subsequent 14 days, after which the slices were fixed and immunostained. (B) Representative confocal images displaying GFP +
cells (green; NSCs) and MBP (red) immunoreactivity after 14 days of treatment. Scale bar = 20µm. (C) MBP intensity was measured using Image-Pro. (D) GFP +
MBP + intensity was measured using Image-Pro. Representative images are shown, and quantitative data refer to mean ± SD (n = 6 slices/group). **p < 0.01, ***p <
0.001. One-way ANOVA with Tukey’s multiple comparisons test and unpaired Student’s t-test. One representative of 3 independent experiments is shown.
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FIGURE 2 | Impact of FTY720 plus NSC treatment on neural cell lineages in brain slice culture model. Brain slices obtained from newborn (P0-3) C57/Bl6 mouse
pups were grown for 3 days in culture, and NSCs (2 µl, ∼ 5 × 104 cells /slice) and/or FTY720 (1 nM) were added for the subsequent 7 days; the slices were then fixed
and immunostained. (A) Quantitative analysis of the number of transplanted NSCs (GFP+) in brain slices. (B) Immunofluorescence images of brain slices. Cells
co-labeled with GFP and neural specific markers (red) were identified as differentiated cells derived from NSCs (yellow); cells positive only for neural-specific markers
(red) were endogenous cells. CC1+: oligodendrocytes, NeuN+: neurons, GFAP+, astrocytes. Scale bar = 20µm. (C) High-magnification confocal images show that
(Continued)
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FIGURE 2 | GFP (green) was highly colocalized with the oligodendrocyte marker MBP (red). Scale bar = 10µm. (D) Quantification of total CC1+ cell numbers.
(E) Quantitative analysis of differentiation of transplanted NSCs in the CNS as shown in (B). Symbols represent mean ± SD; n = 10 random areas per group.
***p < 0.001. One-way ANOVA with Tukey’s multiple comparisons test and unpaired Student’s t-test. One representative of 3 independent experiments is shown.
Myelination of Shiverer Mice
Newborn double-homozygous shiverer (shi/shi) mice (The
Jackson Laboratory, Bar Harbor, ME) were implanted with
dissociated single NSCs, with or without FTY720 from the
day of cell injection. NSCs were transplanted bilaterally in the
corpus callosum of newborn shiverer mice (2.0 × 105/mouse)
starting from 0 to 2 days of age, following a protocol using
hematopoietic stem cell transplantation (Windrem et al., 2004).
Shiverer mice that received NSCs, or FTY720 (injected i.p. at
0.3 mg/kg daily) alone served as single-treatment controls, and
mice that received the same volume of PBS served as a sham-
treated control. The mice were then returned to their mothers,
and allowed to develop normally, with weaning at 28 days and
small group housing thereafter. At 3 months of age, mice were
anesthetized, perfused, and brains were isolated for FluoroMyelin
staining, an indicator of mature myelin formation. FluoroMyelin
green fluorescent myelin stain was performed following the
manufacturer’s instructions (ThermoFisher Scientific). Kaplan-
Meier analysis was used to assess the survival of shiverer mice in
different groups, as described (Shinkai et al., 1992).
Real-Time RT-PCR
Total RNA was extracted from spinal cords using RNeasy R©
Plus Mini Kit (QIAGEN, Valencia, CA) according to the
manufacturer’s instructions. Reverse transcription was
conducted using QuantiTect R© Reverse Transcription Kit
(Qiagen, Valencia, CA). Real-time PCR was performed using
the Custom RT² Profiler PCR Array (Qiagen, Valencia, CA) for
mouse growth factors (Cat. no. 330231 PAMM-041ZA), and
detection was performed using the ABI Prism R© 7500 Sequence
Detection System (Applied Biosystems, Foster City, CA).
Immunohistochemical Analysis
Results were visualized by fluorescent microscopy (Nikon Eclipse
E600; Nikon, Melville, NY) or confocal microscopy (Zeiss
LSM 510; Carl Zeiss, Thornwood, NY). Quantitative image
analysis was performed using ImageJ (NIH) and ImagePro
(Media Cybernetics). To quantify FluoroMyelin, MBP, NFH,
or GFAP expression, pixel intensity immunofluorescence was
measured. All slides were immunostained with MBP, NFH or
GFAP antibodies, and all digital images were acquired using
the same exposure parameters. Pixel intensity of different
markers was measured in disease lesions in the same image
size using ImagePro software (Media Cybernetics). The mean
pixel intensity was calculated from 20 to 25 images per mouse,
5 mice per group were evaluated. To quantify CC1+, NeuN+,
or transplanted GFP+ cells within the slices, 5–10 digital
photographs were taken using the same exposure parameters
from each section, and 5 mice per group were evaluated. Cell
counter of ImagePro software (Media Cybernetics) was used to
count cells, and mean numbers were used for analysis.
Electron Microscopy
Mice were deeply anesthetized and perfused with 4%
paraformaldehyde, 1.5% glutaraldehyde and 1mM CaCl2
in 0.1M cacodylate buffer. The spinal cords were exposed
and fixed in the same solution at 4◦C for 24 h. Samples were
washed, post-fixed with 1% OsO4 in 0.1M PBS (pH 7.4) for 2 h
at room temperature, and subsequently dehydrated in graded
ethanol series. Embedding was performed in TAAB resin.
Sections, 1.0µm thick, were cut, stained in toluidine blue (1%),
and examined by light microscopy (E800, Nikon) for general
histological assessment. Ultrathin sections (60–80 nm) were cut,
viewed and photographed with a HT7700 (Hitachi) transmission
electron microscope operated at 120 kV. Images were analyzed
in Image-Pro for thickness of myelin sheath and g-ratio.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6
software (GraphPad, La Jolla, CA). Data are presented as
mean ± SD. When comparing multiple groups, data were
analyzed by analysis of variance (ANOVA) with Tukey’s multiple
comparisons test. A significance criterion of p < 0.05 was used
for all statistical analysis.
RESULTS
FTY720 Drives Transplanted NSCs to
Differentiate Into Oligodendrocytes and
Promotes Myelination in an ex vivo
Organotypic Slice Culture Model
The beneficial effects of FTY720 on NSC differentiation into
oligodendrocytes in vitro (Zhang et al., 2017) prompted us
to investigate whether FTY720 could enhance myelination
and myelin maintenance under nonpathological conditions
in an ex-vivo culture of brain slices, which maintain the
true three-dimensional structure of the tissue (Humpel, 2015).
To this end, following 3 days of recovery from dissection
in culture, dissociated single NSCs and/or FTY720 were
added to mouse brain slices for the subsequent 2 weeks.
Experimental design and treatment strategies are shown in
Figure 1A. After 14 days, some exogenous GFP-positive NSCs
were attached on the surface, or the edge of the slice, but
others penetrated into the tissue slice structure, matured and
myelinated (Figure 1B). Co-treatment with FTY720 and NSCs
remarkably increased the area and intensity of MBP staining
per field relative to sham-treated control (∼2.86 fold over
control, p = 0.0005), while a single treatment (either NSCs
or FTY720) resulted in a slight, but significantly greater,
improvement in myelin maintenance than in the sham-treated
control group (Figure 1C). Interestingly, while NSCs (GFP+)
without FTY720 injection did not express MBP, a large
proportion (∼29%) of those with FTY720 did so, indicating
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FIGURE 3 | Co-treatment with FTY720 and NSCs promoted myelination in the CNS of newborn mice in vivo. (A) Schematic diagram illustrating experimental design
followed throughout this study. Mice were i.c.v. injected with NSCs (2 µl, ∼2 × 105 cells/mouse) at day 3 postnatal, then injected daily with FTY720 i.p. (0.3
mg/mouse) or with PBS from day 3 postnatal. Spinal cords were harvested at day 14 postnatal, and stained with antibodies to MBP for myelin and to NFH for axonal
fibers. (B) Representative confocal images displaying NFH (green) and MBP (red) immunoreactivity. Scale bar = 10µm. (C) Quantification of myelinated axons from
the total number of axons in 5 mouse litters each group, performed within 5 random standard 500 µm2 fields in the white matter of the ventral lumbar. (D)
Representative electron micrographs of transverse lumbar sections of the ventral region. Scale bar = 1.0µm. (E) Quantification of the mean thickness of myelin
sheaths. (F) Mean g ratio (axon diameter divided by the entire myelinated fiber diameter) was determined using Image-Pro Plus software. Symbols represent mean ±
SD. *p < 0.05, **p < 0.01. One-way ANOVA with Tukey’s multiple comparisons test and unpaired Student’s t-test.
that FTY720 not only enhanced brain tissue myelination, but
also promoted NSC differentiation into mature oligodendrocytes
(Figure 1D).
We next investigated the effects of FTY720 on the fate of
NSCs in the cultures by labeling them with neural cell-specific
antibodies after 7 days of FTY720 treatment. A significantly
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increased number of NSCs (GFP+) was observed in FTY720
and NSC co-treated wells compared to the single NSC treatment
group. Quantitative analysis showed that approximately 847
± 59 GFP+ cells/mm2 were found in the brain slice of the co-
treatment group, while approximately 337± 56 GFP+ cells/mm2
were found in slices treated with NSCs alone (Figure 2A).
Co-localization of GFP+ and neural-specific markers revealed
the differentiation of transplanted NSCs into CC1+ mature
OLGs and NeuN+ neurons (Figure 2B). Rare GFP+ NSC
colocalizing with GFAP was observed in mice treated with NSCs
alone or in combination with FTY720 (Figures 2B,E), while
the co-treatment globally reduced the number and branches
of astrocytes compared to other groups (Figure 2B). High-
magnification confocal images further confirmed that the grafted
NSCs differentiated into MBP+ mature oligodendrocytes with
membrane elaboration (Figure 2C). Further, the numbers of
CC1+ OLGs as well as transplanted CC1+ GFP+ OLGs in the
NSC plus FTY720 co-treated groupwere significantly higher than
in those treated with NSCs alone (Figures 2D,E). The numbers
of NeuN+ GFP+ neurons were similar (Figure 2E). Together,
these results indicate that FTY720 not only enhanced formation
of myelin sheaths in brain slice cultures, but also promoted
survival of NSCs, adding and driving their differentiation
into mature oligodendrocytes, thus further promoting
myelination.
The Effects of FTY720 And/Or NSC
Treatment on CNS Myelinogenesis
Myelinogenesis, the establishment of the myelin sheath in the
mammalian nervous system, occurs predominantly postnatally
within the first 3 weeks in rodents (Hughes and Appel,
2016). To investigate whether FTY720 or/and NSCs can
affect myelinogenesis and oligodendrogenesis in the developing
nervous system under nonpathological conditions, myelination
extent was quantified in the spinal cord of newborn mice at day
14 postnatal, when myelination was not complete (Figure 3A).
Up to 77% of the myelinated axons (co-localization of NFH and
MBP) were observed in PBS-injected mice, while∼81% and 80%
myelinated axons were detected in mice treated with FTY720 or
NSCs alone, respectively, while there was no obvious increase
in myelination compared with the PBS-injected littermates.
Notably, in the group with FTY720 and NSC co-treatment, the
extent of myelinated axons was remarkably increased compared
with the PBS-injected littermates and those treated with either
FTY720 or NSCs alone (p< 0.05; Figures 3B,C).
To further evaluate the effects of FTY720 or/and NSCs on
CNS myelination, ultrastructural EM was applied to determine
myelin layer thickness, as well as axonal size (Figures 3D–F).
Consistent with the findings obtained by immunohistochemistry,
thicker myelin sheath was found in the FTY720 and NSC co-
treatment group compared with the PBS-injected littermates
(Figures 3D,E). This was also manifested in the averaged g-ratio
(the ratio between diameter of axon and total fiber) obtained at
postnatal day 14 (Figure 3F). These results clearly indicate an
accelerated myelin development induced by FTY720 and NSCs
in the CNS.
The numbers of CC1+ cells, the newly matured
oligodendrocytes, were then quantified in the spinal cord
at day 14 postnatal. Consistent with the myelination results
shown in Figure 3, the numbers of CC1+ oligodendrocytes were
significantly increased in both the FTY720 and NSCs-single
treated groups (∼1.25 and 1.33-fold higher), vs. PBS-treated
control littermates (Figures 4A,B). In the NSC and FTY720
co-treated group, a ∼2.75-fold increase in the number of
CC1-expressing cells was detected at day 14 postnatal,
in comparison to the PBS-injected littermates, which was
significantly higher than in the other three groups. These results
indicate the combined effects of promoting myelinogenesis and
oligodendrogenesis in the developing nervous system under
nonpathological conditions.
We further studied the effects of postnatal administration
of FTY720 and/or NSCs on the expression of several growth
factors, given the essential role of these growth factors in CNS
development (Acosta et al., 2013). As shown in Figure 4C,
single- and co-treatment regulated the expression of several
growth factors and neurotrophins, including BDNF, GDNF,
T3, NT3, LIF, IGF1, IL6, SHH, NGF, GDF11, in varying
degrees; while the fold change in the FTY720 and NSC co-
treated group was most remarkable. The results indicate that
single-NSC treatment may also induce a trophic effect per
se, and that the co-treatment with FTY720, even though
beneficial in myelination improvement, does not have a direct
effect on this specific mechanism. Among the differentially
expressed genes, the most robustly induced (∼30-fold higher
over PBS control) were brain-derived neurotrophic factor
(BDNF) and glial cell line-derived neurotrophic factor
(GDNF), important growth factors produced by CNS
cells, promoting NSC survival and improving neurogenesis.
Collectively, FTY720 and NSC treatment significantly promoted
myelination in the CNS, most likely through creating a
beneficial environment, e.g., induction of neurotrophic
factors.
Although immunohistochemical studies showed significant
differences, mice in different groups demonstrated no gross
morphological abnormalities, bred efficiently, and demonstrated
comparable body weights to controls throughout development
(data not shown). To determine if the accelerated myelin
development induced by FTY720 and/or NSC resulted in any
advantage in sensor/motor function, we performed a behavioral
assessment of littermate mice from four different groups at days
20–21 postnatal. An open-field test was performed to assess
anxiety and voluntary locomotor activity at day 20 postnatal, and
the balance and motor coordination of the mice were evaluated
using a rotating rod test at day 21 postnatal. In the open-field
test, mice in neither the single- nor the co-treatment group made
significantly different stops compared with their PBS-injected
littermates, indicating no difference in the anxiety indices among
the four groups in this test (data not shown). In the rotating
rod test at accelerating speed (Figure 4D), FTY720 and NSC co-
treatment mice exhibited a significantly longer latency in falling
off the rod than the other three groups of mice (an increase of
1.43-fold in the time they stayed on the rotating rod). These
findings suggest the improvement brought about by FTY720 and
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FIGURE 4 | The effect of co-treatment with FTY720 and NSCs on the number of mature oligodendrocytes in the spinal cord of newborn mice. Spinal cords of mice
described in Figure 3 were harvested at day 14 postnatal, and lumbar sections were stained for newly matured oligodendrocyte marker CC1. (A) Representative
confocal images displaying CC1+ (red) immunoreactivity at day 14 postnatal. Scale bar = 10µm. (B) Quantification of total CC1+ cell numbers. (C) Expression of
growth factor genes in brain tissues was determined using Custom RT² Profiler
TM
PCR Array Mouse Growth Factors (Qiagen, Valencia, CA). Relative expression was
calculated by –11Ct values from triplicate of PCR (n = 3; mean + SEM, Student’s t-test; normalized to PBS group). (D) The effect of postnatal FTY720 or/and NSC
administration on the performance of newborn mice in accelerating rotating rod test was examined at day 21 postnatal. Symbols represent mean ± SD. *p < 0.05,
**p < 0.01, ***p < 0.01. One-way ANOVA with Tukey’s multiple comparisons test and unpaired Student’s t test.
NSC co-treatment in balance and motor coordination of the
newborn mice.
Transplanted NSCs Prolonged the Survival
of Shiverer Mice, and FTY720 Significantly
Enhanced This Effect
To further confirm the direct effect of FTY720 on the in vivo
development of NSCs into myelinating cells, the shiverer mouse
model was included. Shiverer mice have a spontaneous deletion
of multiple exons in the gene encoding myelin basic protein
(MBP), resulting in pronounced ataxia by 2–3 weeks of age, as
well as the onset of fatal seizures by∼8–14 weeks (Windrem et al.,
2008). Congenitally hypomyelinated shiverermice fail to generate
compact myelin and die by 18∼21 weeks of age. Thus, any
myelin produced by NSCs transplanted into a shiverer CNS can
be unambiguously identified by positive immunohistochemical
staining for MBP (Wang et al., 2013).
Predictably, untreated shiverer mice exhibited markedly
impaired forward ambulation and frequent episodes of sustained
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seizures. Over a range of 85–106 days postnatally, all the
PBS-treated and FTY720-treated shiverer mice died, with a
median survival of 95.4 and 95.0 days, respectively. No obvious
differences were observed between these two groups (Figure 5A).
Animals transplanted with NSCs exhibited a significantly
prolonged survival, with an average survival of approximately
105.8 days. Remarkably, the proportion of surviving shiverer
mice was greater in the FTY720+NSC co-treated group than in
the group engrafted with NSC only, with an average survival of
114.6 days.
FTY720 in Combination With Transplanted
NSCs Improved Neurological Function and
Diminished Seizures of Shiverer Mice
Shiverer mice typically exhibit truncal instability and marked
intention tremor, evident within a few weeks of birth, which
becomes complicated by a progressive hindlimb weakness, such
that by 95–105 days of age, they are severely impaired and
manifest status epilepticus (Video 1) until they died. Given the
substantially longer survivals noted in the FTY720-NSC co-
treated shiverer, we then tested whether neurological function
was improved after treatment. We noted that all groups of the
shiverer, treated or untreated, deteriorated identically over the
first few weeks after birth. However, up to 100 days, the point at
whichmice typically began to die, little difference was observed in
the behavior of co-treated relative to NSC single-treated shiverer
mice. All those mice survived the period spanning 120–150
days postnatally, and exhibited noticeable improvement in their
neurological function manifested by diminished frequency of
seizures and improved ambulation (Video 2). We also quantified
the neurological improvements∼100 days of age (Figures 5B,C).
Shiverer mice treated with NSCs alone as well as FTY720/NSC
co-treatment exhibited a significantly shorter duration but longer
intervals of episodes than the PBS or FTY720 single-treated
groups of mice (Figures 5B,C). However, at this time point,
no remarkable difference was observed in the neurological
improvement of the co-treatment group relative to NSC single-
treated shiverer mice (Figures 5B,C). Accordingly, NSCs or
FTY720+NSC co-treated groups exhibited markedly improved
neurological function, with decreased seizure incidence and
improved mobility and self-care compared to mice treated with
PBS or FTY720 alone.
FTY720 in Combination With Transplanted
NSCs Efficiently Myelinated the Shiverer
Brain
To assess the extent of myelination in shiverer mice with
different treatments, myelin production was analyzed by MBP
immunohistochemistry at day 90 postnatal (Figure 6A). In mice
treated with PBS or FTY720, the absence of MBP leads to an
almost complete lack of myelin stain in the brain (Figure 6A).
In contrast, myelination of the brain was exhibited in the NSC
or FTY720+NSC transplanted mice, which survived beyond 3–
5 months. Remarkably, the degree of myelination, as well as
the survival rate, was greater in FTY720-NSC co-treated mice
than in mice only engrafted with NSCs (Figure 6). Together,
these data indicate that engrafted NSCs can efficiently myelinate
the hypomyelinated shiverer brain, and FTY720 significantly
enhances this effect.
DISCUSSION
The appearance of myelin, and especially myelinogenesis
postnatally, was a crucial step in vertebrate evolution and
proper functioning of the mammalian CNS (Figlia et al.,
2018). Impairment in myelin-producing cell (oligodendrocyte)
development and subsequent myelination deficits appear as
a common denominator of demyelinating diseases, ranging
from pediatric leukodystrophies and cerebral palsy, to MS
and white matter stroke (Goldman et al., 2012). Chronic
demyelinating diseases also play a role in the pathogenesis
of other neurological diseases, such as stroke, amyotrophic
lateral sclerosis, and Alzheimer’s disease (Höftberger and
Lassmann, 2017). Accordingly, replacing lost oligodendrocytes
by endogenous or exogenous progenitor cells, such as NSCs or
OPCs, holds great promise as a therapeutic strategy (Goldman
et al., 2012). However, stem cell therapy alone is limited for
clinical and pathological improvement, especially in chronic
demyelinating diseases, because of its relatively slow rate of
oligodendrocyte differentiation (Franklin and Ffrench-Constant,
2008). It has been demonstrated that the primary cause of
stem cell inefficiency is that the hostile, sustained inflammation
stress and loss of trophic support weaken cell viability and
differentiation capacity, and even cause intrinsic defects in
transplanted NSCs or other multipotent stem cells in CNS lesions
(Gao et al., 2014). Therefore, strategies targeted at suppressing
CNS inflammation, converting a hostile environment for
transplanted cells into a supportive one, and promoting
OLG maturity, could be ideal for the treatment of chronic
demyelinating diseases (Xiao et al., 2018).
In our previous study, we demonstrated an effective
therapy combining FTY720 and transplanted NSCs that
significantly alleviated the chronic stage of relapsing-remitting
EAE (Zhang et al., 2017). The therapeutic effects correlated
with not only the reduction of demyelination, promotion
of remyelination of the EAE pathological process, inhibition
of axonal degeneration and astrogliosis, but also with the
efficient improvement of survival of transplanted NSCs and
promotion of development of OPCs into OLGs in vivo (Zhang
et al., 2017). Although these results are encouraging, there
remained the question whether the neuroprotective effect
with FTY720 and NSCs is a secondary consequence of the
immunomodulatory activity in the inflamed CNS or could
also be manifested under nonpathological conditions. Here we
attempted to address this important question and investigate the
direct effects of the combination therapy on myelinogenesis and
oligodendrogenesis in the developing nervous system by using
three myelination models without the involvement of immune
responses.
Numerous studies in vitro had demonstrated that FTY720
induces OPC process extension and differentiation in every
instance (Coelho et al., 2007; Jung et al., 2007; Miron et al.,
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 February 2019 | Volume 13 | Article 14
Zhang et al. Fingolimod and NSCs Promote Myelination
FIGURE 5 | FTY720 in combination with transplanted NSCs improved neurological function and diminished seizures of shiverer mice. (A) Transplanted NSCs and
FTY720-NSC co-treatment prolong the survival of shiverer mice. Newborn double-homozygous shiverer (shi/shi) mice were implanted i.c.v. with dissociated single
NSCs (2.0 × 105 cells/mouse), and injected i.p. with fingolimod (at 0.3 mg/kg daily) (n = 12) from the day of cell injection. Shiverer mice that received NSCs (n = 14),
or fingolimod (n = 12) alone served as single-treatment controls, and mice that received the same volume of phosphate-buffered saline (PBS) served as a
sham-treated control (n = 12). All these shiverer mice were maintained in small group housing and monitored daily until death. The Kaplan-Meier survival graph,
plotting the percentage of each group alive in days, is shown. (B) Quantification of length of episodes. (C) Quantification of intervals of episodes. Symbols represent
mean ± SD. ***p < 0.01. One-way ANOVA with Tukey’s multiple comparisons test and unpaired Student’s t test.
2008a; Bieberich, 2011; Cui et al., 2014). Although cultures
of oligodendrocyte lineage cells have been frequently used
to study aspects of oligodendroglia cell biology, the obvious
weakness of the in vitro cell culture system is that it does not
accurately recapitulate the complex 3-D structure of tissue, and
the cells behave “abnormally” in very contrived environments
(Jarjour et al., 2012). An alternative is to use an ex vivo
brain slice culture model, in which the myelination process
happens within a multicellular environment that maintains
physiological cell-cell interactions (Zhang et al., 2011). It can
be used as an intermediate step between in vitro experiments
and undertaking lengthy in vivo studies. In a previous study,
Miron and colleagues (Miron et al., 2010) reported that
FTY720 alone had no impact on myelination of brain slices
under basal conditions. We also observed similar results in
the single FTY720-treated group. However, when we treated
brain slices from newborn mice with FTY720 plus NSCs, we
found that FTY720 could drive NSCs to differentiate into
oligodendrocytes and promote myelination significantly in an
ex vivo brain slice culture model. In addition, NSCs may have
trophic effects by releasing neurotrophic factors BDNF and
GDNF, which alter the behavior of endogenous OPCs, promoting
their maturation and myelination (De Feo et al., 2012). We
speculated that these results were most likely due to S1P
receptor expression or that the response of endogenous precursor
cells (OPCs or NSCs) was modulated by the environment
with inflammation stress, and the promising results of the
combination therapy suggested that supplying FTY720 could
induce a growth-promoting environment for endogenous OLG
generation by transplanted NSCs, thus effectively promoting
myelinogenesis.
We then further verified the potential of the combination
therapy to promote postnatal myelinogenesis in healthy newborn
mice as well as in shiverer mice with MBP gene deletion.
The cumulative findings, obtained by both immunohistological
and biochemical analyses, indicated that FTY720 treatment
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FIGURE 6 | FTY720 in combination with transplanted NSCs efficiently myelinated the shiverer brain. In separate experiments, mice were treated as described in
Figure 5, and brains were harvested at day 90 postnatal for immunostaining. (A) Confocal micrographs showing FluoroMyelin staining in the midline of the corpus
callosum of shiverer mice treated with NSCs and/or FTY720. (B) Averaged values (mean ± SEM) of myelin signal density in the midline of the callosal body from
treatment groups shown in (A). *p < 0.05, **p < 0.01. One-way ANOVA with Tukey’s multiple comparisons test and unpaired Student’s t-test. One representative of 3
independent experiments is shown.
alone did not obviously affect myelination, and NSC treatment
alone resulted in a slight, but significant, improvement.
Notably, a remarkable increase in the number of myelin-
encircled axons and CC1+ mature oligodendrocytes could
be detected in the CNS of 14-day-old mice co-treated with
FTY720 and NSCs, compared to the single- or PBS-treated
littermates. The increased myelinogenesis that resulted from
FTY720 and NSC co-treatment, obtained in this study in
both healthy and genetically defective infant mice, is in
accord with our previous findings, which indicated similar
effects in mature EAE-induced mice (Zhang et al., 2017).
Likewise, it was demonstrated that a novel mechanism of
FTY720 action in NSC differentiation and remyelination.
Taken together, our in vivo findings demonstrate that FTY720
and NSC co-treatment accelerated myelin development in
the newborn mice at non-inflammatory conditions, thus
confirming a direct, immunomodulation-independent effect for
myelination.
The underlying mechanism by which FTY720 and NSCs
affect myelinogenesis and oligodendrogenesis in the developing
nervous system under nonpathological conditions was attributed
to a neurotrophic effect, namely, a modulation of growth factor
expression. In this study, an increase in the expression of BDNF,
GDNF, T3, NT3, LIF, IGF1, IL6, SHH, NGF, and GDF11 was
demonstrated following the co-treatment in the CNS of the infant
mice, and among them the increase in BDNF and GDNF was
more prominent than in the others. These neurotrophins had
been shown to promote myelination and regeneration during
development as well as under pathological conditions (Acosta
et al., 2013), and the observed effects of FTY720 and NSCs
on myelination during postnatal development may result in
part from the increased expression of beneficial growth factors.
Also, the improved sensorimotor function observed at day 21
postnatal, as manifested by the co-treatment group exhibiting
a better performance in the rotating rod test than their PBS-
injected littermates, could be attributed to the lasting benefit
of these growth factors, which positively influence myelin
development and behavioral manifestations in the developing
CNS.
Although remyelination activities of FTY720 treatment
in chemical-induced non-inflammatory and EAE-induced
inflammatory demyelination models have been reported
(Slowik et al., 2015; Yazdi et al., 2015; Zhang et al., 2017),
two advantages of using healthy or shiverer infant mice over
EAE and the cuprizone-induced demyelination model are
(Windrem et al., 2008; Wang et al., 2013): (1) unlike EAE mice,
these models have a minimal (or none at all) immunological
component such as microglia activation in the CNS, with no
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involvement of infiltrating immune cells from the periphery;
(2) unlike cuprizone-induced demyelination, the mouse models
do not involve chemical toxicity to myelinating cells in the
CNS. Taken together, the myelination models in this study
provided evidence for the direct effect of FTY720 on NSC
differentiation into oligodendrocytes, as well as that FTY720
promoted myelination by NSCs in vivo, in addition to its
well-known immunomodulatory effects. The results also
provide useful information on other neurological disorders
with similar characteristics (minimal CNS inflammation and
non-chemical-induced), such as neurodegenerative diseases.
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